TY - JOUR T1 - Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease JF - Evidence Based Medicine JO - Evid Based Med SP - 15 LP - 15 DO - 10.1136/ebm.10.1.15 VL - 10 IS - 1 A2 - , Y1 - 2005/02/01 UR - http://ebm.bmj.com/content/10/1/15.abstract N2 - AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105–15.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In patients with Alzheimer’s disease (AD), does donepezil delay entry to institutional care or progression of disability? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Neurology ★★★★★★☆ Geriatrics ★★★★★★☆ Design: randomised controlled trial (AD2000 study). Allocation: {concealed*}†. Blinding: blinded {patients, healthcare providers, data collectors, and outcome assessors}†.* Follow up period: 3 years. Setting: 22 hospitals in the UK. Patients: 566 patients (59% women, median age 75–76 y) who were referred to memory clinics with a suspected DSM-IV diagnosis of dementia of Alzheimer type, with or without coexisting vascular dementia; had a regular carer; lived in the community; were not taking a cholinesterase inhibitor; and had no contraindications to donepezil. Intervention: during a 12 week run in period, patients were allocated to donepezil, 5 mg/day (n = 283), or … ER -